Dr. Black on Combinations with Durvalumab in Bladder Cancer

Peter Black, MD
Published Online: Tuesday, May 16, 2017



Peter Black, MD, senior research scientist, Vancouver Prostate Center, associate professor, Department of Urologic Sciences, University of British Columbia, discusses combination trials with durvalumab (Imfinzi) for patients with bladder cancer.

Durvalumab works as a monotherapy for the second-line setting after cisplatin therapy, explains Black. In the first-line setting there is a combination trial of durvalumab versus durvalumab plus tremelimumab versus standard chemotherapy.

In other disease sites, the combination works well—making people very optimistic but the results will take a few years, states Black.
 


Peter Black, MD, senior research scientist, Vancouver Prostate Center, associate professor, Department of Urologic Sciences, University of British Columbia, discusses combination trials with durvalumab (Imfinzi) for patients with bladder cancer.

Durvalumab works as a monotherapy for the second-line setting after cisplatin therapy, explains Black. In the first-line setting there is a combination trial of durvalumab versus durvalumab plus tremelimumab versus standard chemotherapy.

In other disease sites, the combination works well—making people very optimistic but the results will take a few years, states Black.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment and Management of CINVJul 26, 20171.5
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Genitourinary CancersJul 28, 20171.5
Publication Bottom Border
Border Publication
$emailPop$